Skip to main content
Top
Published in: Osteoporosis International 10/2017

01-10-2017 | Short Communication

The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial

Authors: F. D. Wolinsky, S. F. Hall, Y. Lou, S. W. Edmonds, K. G. Saag, D. W. Roblin, N. C. Wright, M. P. Jones, P. Cram, J. R. Curtis, S. L. Morgan, J. A. Schlechte, J. H. Williams, D. J. Zelman, on behalf of the PAADRN Investigators

Published in: Osteoporosis International | Issue 10/2017

Login to get access

Abstract

Summary

In a large, pragmatic clinical trial, we calculated the costs of achieving four successful patient-centered outcomes using a tailored patient activation DXA result letter accompanied by a bone health brochure. The cost to achieve one successful outcome (e.g., a 0.5 standard deviation improvement in care satisfaction) ranged from $127.41 to $222.75.

Introduction

Pragmatic randomized controlled trials (RCTs) should focus on patient-centered outcomes and report the costs for achieving those outcomes. We calculated per person incremental intervention costs, the number-needed-to-treat (NNT), and incremental per patient costs (cost per NNT) for four patient-centered outcomes in a direct-to-patient bone healthcare intervention.

Methods

The Patient Activation after DXA Result Notification (PAADRN) pragmatic RCT enrolled 7749 patients presenting for DXA at three health centers between February 2012 and August 2014. Interviews occurred at baseline and 52 weeks post-DXA. Intervention subjects received an individually tailored DXA result letter accompanied by an educational bone health brochure 4 weeks post-DXA, while the usual care subjects did not. Outcomes focused on patients (a) correctly identifying their results, (b) contacting their providers, (c) discussing their results with their providers, and (d) satisfaction with their bone healthcare. NNTs were determined using intention-to-treat linear probability models, per person incremental intervention costs were calculated, and costs per NNT were computed.

Results

Mean age was 66.6 years old, 83.8% were women, and 75.3% were non-Hispanic whites. The incremental per patient cost (costs per NNT) to increase the ability of a patient to (a) correctly identify their DXA result was $171.07; (b) contact their provider about their DXA result was $222.75; (c) discuss their DXA result with their provider was $193.55; and (d) achieve a 0.5 SD improvement in satisfaction with their bone healthcare was $127.41.

Conclusion

An individually tailored DXA result letter accompanied by an educational brochure can improve four patient-centered outcomes at a modest cost.

Trial registration

clinicaltrials.​gov identifier NCT01507662
Literature
1.
go back to reference Schwartz D, Lellouch J (1967) Explanatoy and pragmatic attitudes in therapeutic trials. J Chron Dis 20:637–648CrossRefPubMed Schwartz D, Lellouch J (1967) Explanatoy and pragmatic attitudes in therapeutic trials. J Chron Dis 20:637–648CrossRefPubMed
2.
go back to reference Sox HC, Lewis RJ (2016) Pragmatic trials: practical answers to “real world” questions. JAMA 316:1205–1206CrossRefPubMed Sox HC, Lewis RJ (2016) Pragmatic trials: practical answers to “real world” questions. JAMA 316:1205–1206CrossRefPubMed
3.
go back to reference Ford I, Norrie J (2016) Pragmatic Trials N Engl J Med 375: 454–463. doi: 10.1056/NEJMra1510059 Ford I, Norrie J (2016) Pragmatic Trials N Engl J Med 375: 454–463. doi: 10.1056/NEJMra1510059
9.
go back to reference Burge R, Dawson-Hughes B, Solomon D et al (2014) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475. doi:10.1359/jbmr.061113 CrossRef Burge R, Dawson-Hughes B, Solomon D et al (2014) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475. doi:10.​1359/​jbmr.​061113 CrossRef
13.
go back to reference Cram P, Wolinsky FD, Lou Y et al (2016) Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int 27:3513–3524. doi:10.1007/s00198-016-3681-9 CrossRefPubMed Cram P, Wolinsky FD, Lou Y et al (2016) Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int 27:3513–3524. doi:10.​1007/​s00198-016-3681-9 CrossRefPubMed
17.
go back to reference Cram P, Schlechte J, Christensen A (2006) A randomized trial to assess the impact of direct reporting of DXA scan results to patients on quality of osteoporosis care. J Clin Densitom 9:393–398CrossRefPubMed Cram P, Schlechte J, Christensen A (2006) A randomized trial to assess the impact of direct reporting of DXA scan results to patients on quality of osteoporosis care. J Clin Densitom 9:393–398CrossRefPubMed
18.
go back to reference Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733CrossRefPubMed Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733CrossRefPubMed
19.
go back to reference Sanders GD, Neumann PJ, Basu A et al (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316:1093–1103. doi:10.1001/jama.2016.12195 CrossRefPubMed Sanders GD, Neumann PJ, Basu A et al (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316:1093–1103. doi:10.​1001/​jama.​2016.​12195 CrossRefPubMed
20.
go back to reference Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (2017) Cost-effectiveness in health and medicine, 2nd edn. Oxford University Press, New York Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (2017) Cost-effectiveness in health and medicine, 2nd edn. Oxford University Press, New York
Metadata
Title
The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial
Authors
F. D. Wolinsky
S. F. Hall
Y. Lou
S. W. Edmonds
K. G. Saag
D. W. Roblin
N. C. Wright
M. P. Jones
P. Cram
J. R. Curtis
S. L. Morgan
J. A. Schlechte
J. H. Williams
D. J. Zelman
on behalf of the PAADRN Investigators
Publication date
01-10-2017
Publisher
Springer London
Published in
Osteoporosis International / Issue 10/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-017-4113-1

Other articles of this Issue 10/2017

Osteoporosis International 10/2017 Go to the issue